These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26456308)

  • 1. Preliminary experience with intravenous gadoxetate disodium as a craniospinal MR contrast agent.
    McKinney AM; Gawande R; Pezeshk P; Truwit CL; Rykken JB
    Eur J Radiol; 2015 Dec; 84(12):2539-47. PubMed ID: 26456308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.
    Lauenstein T; Ramirez-Garrido F; Kim YH; Rha SE; Ricke J; Phongkitkarun S; Boettcher J; Gupta RT; Korpraphong P; Tanomkiat W; Furtner J; Liu PS; Henry M; Endrikat J
    Invest Radiol; 2015 Jun; 50(6):416-22. PubMed ID: 25756684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetate disodium, a modern hepatospecific MRI contrast agent: Indirect signs for gadolinium deposition in the brain structures with signal intensity increase after intravenous application.
    Holesta M; Weichet J; Wagnerova MG; Lukavsky J; Malikova H
    Neurol India; 2018; 66(6):1771-1775. PubMed ID: 30504579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous gadoxetate disodium and flip angle on hepatic proton density fat fraction estimation with six-echo, gradient-recalled-echo, magnitude-based MR imaging at 3T.
    Park CC; Hamilton G; Desai A; Zand KA; Wolfson T; Hooker JC; Costa E; Heba E; Clark L; Gamst A; Loomba R; Middleton MS; Sirlin CB
    Abdom Radiol (NY); 2017 Apr; 42(4):1189-1198. PubMed ID: 28028556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
    Furlan A; Close ON; Borhani AA; Wu YH; Heller MT
    Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the gallbladder and cystic duct patency with gadoxetate disodium enhanced MR cholangiography: prospective comparison of patients with normal gallbladder function and acute cholecystitis.
    Yacoub JH; Yousuf A; Agrawal G; Thomas S; Appelbaum DE; Oto A
    Acta Radiol; 2015 Jul; 56(7):782-9. PubMed ID: 25009279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
    Davenport MS; Viglianti BL; Al-Hawary MM; Caoili EM; Kaza RK; Liu PS; Maturen KE; Chenevert TL; Hussain HK
    Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI.
    Jang YJ; Cho SH; Bae JH; Kim GC; Ryeom H; Kim HJ; Shin KM; Lee HJ
    Ann Hepatol; 2013; 12(6):926-34. PubMed ID: 24114823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
    Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM
    AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.
    Goshima S; Kanematsu M; Kondo H; Watanabe H; Kawada H; Moriyama N; Bae KT
    AJR Am J Roentgenol; 2013 Sep; 201(3):578-82. PubMed ID: 23971449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
    Davenport MS; Caoili EM; Kaza RK; Hussain HK
    Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
    Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
    Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging.
    Onishi H; Theisen D; Dietrich O; Reiser MF; Zech CJ
    J Magn Reson Imaging; 2014 Jan; 39(1):42-50. PubMed ID: 24339365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice.
    Kromrey ML; Hori M; Goshima S; Kozaka K; Hyodo T; Nakamura Y; Nishie A; Tamada T; Shimizu T; Kanki A; Motosugi U
    Eur Radiol; 2020 Jan; 30(1):281-290. PubMed ID: 31338655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
    Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
    Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses.
    Kim SY; Park SH; Wu EH; Wang ZJ; Hope TA; Chang WC; Yeh BM
    AJR Am J Roentgenol; 2015 Jun; 204(6):1220-7. PubMed ID: 26001231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?
    Pahade JK; Juice D; Staib L; Israel G; Cornfeld D; Mitchell K; Weinreb J
    Abdom Radiol (NY); 2016 Jul; 41(7):1270-84. PubMed ID: 26800701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of contrast-enhanced fluid-attenuated inversion-recovery MRI for intracranial tumors in comparison with post-contrast T1W spin-echo MRI.
    Zhou ZR; Shen TZ; Chen XR; Peng WJ
    Chin Med J (Engl); 2006 Mar; 119(6):467-73. PubMed ID: 16584644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.
    Watanabe H; Kanematsu M; Goshima S; Kondo H; Onozuka M; Moriyama N; Bae KT
    Radiology; 2011 Apr; 259(1):142-50. PubMed ID: 21248234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.